KR20010043563A - 부작용 경감제 - Google Patents
부작용 경감제 Download PDFInfo
- Publication number
- KR20010043563A KR20010043563A KR1020007012687A KR20007012687A KR20010043563A KR 20010043563 A KR20010043563 A KR 20010043563A KR 1020007012687 A KR1020007012687 A KR 1020007012687A KR 20007012687 A KR20007012687 A KR 20007012687A KR 20010043563 A KR20010043563 A KR 20010043563A
- Authority
- KR
- South Korea
- Prior art keywords
- agent
- compound
- tumor
- side effects
- day
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Amplifiers (AREA)
- Electrotherapy Devices (AREA)
- Stereophonic System (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Inorganic Insulating Materials (AREA)
Abstract
Description
화합물(용량,㎎/㎏) | 개체수 | 체중변화(g) | 억제율(%) |
대조 | 8 | 29.3±3.7 | |
5-FU(20) | 8 | 15.6±3.6** | 46.7 |
5-FU(20)+화합물 1(100) | 8 | 23.3±4.8*## | 20.7 |
CDDP(1.0) | 8 | 11.9±5.4** | 59.4 |
CDDP(1.0)+화합물 1(100) | 8 | 17.3±5.7**# | 41.1 |
화합물(용량,㎎/㎏) | 개체수 | 종양중량(g) | 억제율(%) | 체중변화(g) | 체중변화율(%) |
대조 | 8 | 0.666±0.244 | 25.9±9.2 | ||
CDDP(6.0)+0.5%HMPC | 8 | 0.162±0.155 | 75.7 | -19.4±8.6 | 174.9 |
CDDP(6.0)+화합물 1(30) | 8 | 0.167±0.147 | 74.9 | -2.7±12.8 | 110.4 |
CDDP(6.0)+화합물 1(100) | 7 | 0.139±0.131 | 79.1 | -9.1±18.9 | 135.1 |
CDDP(6.0)+화합물 1(300) | 8 | 0.158±0.122 | 76.3 | -7.4±16.3 | 128.6 |
생리식염수+화합물 1(30) | 7 | 0.787±0.307 | -18.1 | -29.3±10.2 | -13.1 |
생리식염수+화합물 1(100) | 8 | 0.816±0.329 | -22.4 | 23.9±6.6 | 7.7 |
생리식염수+화합물 1(300) | 7 | 0.829±0.281 | -24.5 | 28.1±6.0 | -8.5 |
화합물(용량,㎎/㎏) | 개체수 | 체중변화(g) | 체중변화율(%) |
대조 | 6 | 1.4±0.9 | 3.9 |
FTD(200) | 6 | -6.1±4.7** | -17.6 |
FTD(200)+화합물 1(94) | 6 | 0.3±0.7 | 0.7 |
화합물 1(100) | 6 | 2.4±1.1 | 6.8 |
화합물(용량, ㎎/㎏) | 소장 | 대장 | |
IL-6 | 1L-1β | 1L-6 | |
대조 | 16.2±5.9 | 23.9±10.0 | 11.1±5.7 |
FTD(200) | 95.5±19.2** | 77.3±42.1** | 118.0±47.6** |
FTD(200)+화합물 1(94) | 17.2±11.9 | 14.0±4.0 | 11.3±4.6 |
화합물 1(100) | 19.8±9.9 | 23.7±4.6 | 10.7±4.7 |
Claims (12)
- 식(1)로 표시되는 5-클로로-6-(2-이미노피롤리딘-1-일)메틸-2,4(1H,3H)-피리미딘디온 또는 의약으로 허용되는 그의 염을 유효성분으로 하는 항종양제의 부작용 경감제.
- 청구항 1에 있어서, 항종양제의 부작용이 구역질, 구토, 설사, 식욕부진 및 체중감소인 부작용 경감제.
- 청구항 1 또는 2에 있어서, 항종양제가 대사길항제, 알킬화제, 식물유래물질, 항생물질 또는 백금제제인 부작용 경감제.
- 청구항 1 또는 2에 있어서, 항종양제가 5-트리플루오로메틸-2'-데옥시우리딘, 5-플루오로우라실, 염산 이리노테칸 또는 시스프라틴인 부작용 경감제.
- 식(1)로 표시되는 5-클로로-6-(2-이미노피롤리딘-1-일)메틸-2,4(1H, 3H)-피리미딘디온 또는 의약으로 허용되는 그의 염의 항종양제의 부작용 경감제 제조를 위한 사용.
- 청구항 5에 있어서, 항종양제의 부작용이 구역질, 구토, 설사, 식욕부진 및 체중감소인 사용.
- 청구항 5 또는 6에 있어서, 항종양제가 대사길항제, 알킬화제, 식물유래물질, 항생물질 또는 백금제제인 사용.
- 청구항 5 또는 6에 있어서, 항종양제가 5-트리플루오로메틸-2'-데옥시우리딘, 5-플루오로우라실, 염산이리노테칸 또는 시스프라틴인 사용.
- 항종양제를 투여한 환자에게, 식(1)으로 표시되는 5-클로로-6-(2-이미노피롤리딘-1-일)메틸-2,4(1H,3H) -피리미딘디온 또는 의약으로 허용되는 그의 염을 투여하는 것을 특징으로 하는 항종양제의 부작용 경감방법.
- 청구항 9에 있어서, 항종양제의 부작용이 구역질, 구토, 설사, 식욕부진 및 체중감소인 방법.
- 청구항 9 또는 10에 있어서, 항종양제가 대사길항제, 알킬화제, 식물유래물질, 항생물질 또는 백금제제인 방법.
- 청구항 9 또는 10에 있어서, 항종양제가 5-트리플루오로메틸-2'-데옥시우리딘, 5-플루오로우라실, 염산이리노테칸 또는 시스프라틴인 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07757999A JP4049477B2 (ja) | 1999-03-23 | 1999-03-23 | 副作用軽減剤 |
JP11/77579 | 1999-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010043563A true KR20010043563A (ko) | 2001-05-25 |
KR100675044B1 KR100675044B1 (ko) | 2007-01-26 |
Family
ID=13637909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007012687A KR100675044B1 (ko) | 1999-03-23 | 2000-03-16 | 부작용 경감제 |
Country Status (13)
Country | Link |
---|---|
US (2) | USRE47388E1 (ko) |
EP (1) | EP1080726B1 (ko) |
JP (1) | JP4049477B2 (ko) |
KR (1) | KR100675044B1 (ko) |
CN (1) | CN1144587C (ko) |
AT (1) | ATE323494T1 (ko) |
AU (1) | AU772486B2 (ko) |
CA (1) | CA2331737C (ko) |
DE (1) | DE60027369T2 (ko) |
DK (1) | DK1080726T3 (ko) |
ES (1) | ES2261186T3 (ko) |
PT (1) | PT1080726E (ko) |
WO (1) | WO2000056337A1 (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4110347B2 (ja) * | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗hiv剤 |
PL2368553T3 (pl) | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Preparaty farmaceutyczne zawierające metylonaltrekson |
RU2006112548A (ru) * | 2003-09-17 | 2007-10-27 | Айкос Корпорейшн (Us) | Применение ингибиторов снк1 для регуляции пролиферации клеток |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US7820686B2 (en) * | 2006-04-13 | 2010-10-26 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for inflammatory bowel disease |
ES2385850T3 (es) | 2006-06-30 | 2012-08-01 | Taiho Pharmaceutical Co., Ltd. | Potenciador de radioterapia |
ES2540551T3 (es) | 2007-03-29 | 2015-07-10 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
JP2010522756A (ja) | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 結晶形およびその使用 |
AU2008233129B2 (en) | 2007-03-29 | 2014-03-20 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
TWI429439B (zh) * | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
TWI435725B (zh) * | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
AU2009221765B2 (en) * | 2008-03-05 | 2015-05-07 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
DK3012255T3 (da) | 2013-06-17 | 2021-12-06 | Taiho Pharmaceutical Co Ltd | Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil |
CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
CN106333952A (zh) * | 2014-02-19 | 2017-01-18 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
CN103980253B (zh) * | 2014-05-06 | 2015-07-08 | 济南百诺医药科技开发有限公司 | 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法 |
CN105859691A (zh) * | 2016-04-07 | 2016-08-17 | 扬子江药业集团南京海陵药业有限公司 | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 |
EP3565557A4 (en) | 2017-01-09 | 2020-12-02 | Shuttle Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPIES INCLUDING THE ADMINISTRATION OF HALOGENATED THYMIDINES AND THYMIDINE PHOSPHORYLASE INHIBITORS IN COMBINATION WITH RADIATION |
WO2019171394A1 (en) | 2018-03-03 | 2019-09-12 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE245631T1 (de) * | 1995-03-29 | 2003-08-15 | Taiho Pharmaceutical Co Ltd | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel |
KR100284413B1 (ko) | 1996-09-24 | 2001-03-02 | 고바야시 유키오 | 우라실 유도체를 함유하는 암전이 억제제유도체 |
-
1999
- 1999-03-23 JP JP07757999A patent/JP4049477B2/ja not_active Expired - Lifetime
-
2000
- 2000-03-16 KR KR1020007012687A patent/KR100675044B1/ko active IP Right Grant
- 2000-03-16 WO PCT/JP2000/001607 patent/WO2000056337A1/ja active IP Right Grant
- 2000-03-16 EP EP00909678A patent/EP1080726B1/en not_active Expired - Lifetime
- 2000-03-16 DK DK00909678T patent/DK1080726T3/da active
- 2000-03-16 ES ES00909678T patent/ES2261186T3/es not_active Expired - Lifetime
- 2000-03-16 DE DE60027369T patent/DE60027369T2/de not_active Expired - Lifetime
- 2000-03-16 AT AT00909678T patent/ATE323494T1/de active
- 2000-03-16 CA CA002331737A patent/CA2331737C/en not_active Expired - Lifetime
- 2000-03-16 PT PT00909678T patent/PT1080726E/pt unknown
- 2000-03-16 US US15/684,291 patent/USRE47388E1/en not_active Expired - Lifetime
- 2000-03-16 CN CNB008003939A patent/CN1144587C/zh not_active Expired - Lifetime
- 2000-03-16 AU AU31928/00A patent/AU772486B2/en not_active Expired
- 2000-03-16 US US09/701,041 patent/US6479500B1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2331737A1 (en) | 2000-09-28 |
ATE323494T1 (de) | 2006-05-15 |
DK1080726T3 (da) | 2006-08-14 |
USRE47388E1 (en) | 2019-05-14 |
US6479500B1 (en) | 2002-11-12 |
EP1080726A4 (en) | 2003-06-25 |
EP1080726B1 (en) | 2006-04-19 |
CN1144587C (zh) | 2004-04-07 |
PT1080726E (pt) | 2006-07-31 |
CN1297350A (zh) | 2001-05-30 |
WO2000056337A1 (fr) | 2000-09-28 |
DE60027369D1 (de) | 2006-05-24 |
AU772486B2 (en) | 2004-04-29 |
AU3192800A (en) | 2000-10-09 |
ES2261186T3 (es) | 2006-11-16 |
DE60027369T2 (de) | 2006-09-14 |
EP1080726A1 (en) | 2001-03-07 |
JP4049477B2 (ja) | 2008-02-20 |
CA2331737C (en) | 2008-06-17 |
KR100675044B1 (ko) | 2007-01-26 |
JP2000273044A (ja) | 2000-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100675044B1 (ko) | 부작용 경감제 | |
US9814724B2 (en) | Antitumor effect potentiator and antitumor agent | |
KR0148589B1 (ko) | 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트 | |
RU2543348C2 (ru) | Способ лечения путем применения комбинированной терапии | |
RU2268732C2 (ru) | Способы лечения митохондриальных нарушений | |
US6239136B1 (en) | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives | |
KR101401220B1 (ko) | 방사선 치료 증강제 | |
US20100087458A1 (en) | Method of treating melanoma | |
EP1757283A1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
JP2557303B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
TWI434700B (zh) | 放射線治療增強劑 | |
WO1992011247A1 (en) | Anticancer composition and compound | |
US20100087398A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
KR20190124951A (ko) | Pfi-3를 포함하는 신장암의 예방 또는 치료용 조성물 | |
JP2767176B2 (ja) | 抗癌剤 | |
JP3450399B2 (ja) | 血管新生阻害剤 | |
US20040138207A1 (en) | Antitumor agents | |
JPH0624975A (ja) | 制癌活性増強剤 | |
EP2174930A1 (en) | Antitumor agent comprising sulfostin and sulfostin-related compound as the active ingredient | |
JP2006518722A (ja) | 膵臓癌、軟部組織の肉腫、精巣腫瘍、リンパ腫、胸腺腫、ウィルムス腫瘍、腎臓癌、黒色腫、肺腫瘍、脳内転移、頭頸部の腫瘍、および乳癌の処置のための、1−(2−クロロエチル)−1−ニトロソ−3−(2−ヒドロキシエチル)ウレアの使用方法 | |
JP2003300888A (ja) | 抗腫瘍効果増強剤 | |
KR20100131457A (ko) | 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130111 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150105 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161220 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 14 |